
Qiagen rated Buy on new product launches and automation boosting growth despite slow QuantiFERON sales
Qiagen N.V. is rated a Buy due to new product launches like QIAspirant Connect and strategic partnerships with Inpeco/Diasorin and NVIDIA AI, which are expected to drive revenue growth and offset weak demand for QuantiFERON. Management projects 1–2% ...


